๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Malignant Solid Tumor
Clinical trial register · China

Advanced Malignant Solid Tumor Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 7 Beijing 4 Guangzhou 2 Hangzhou 2 Fuzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai7 Beijing4 Guangzhou2 Hangzhou2 Fuzhou1
All 8 locations
Target enrolment
to

Advanced Malignant Solid Tumor trials in China

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases
NCT07697937Advanced Malignant Solid Tumor
Tianjin First Central Hospital
Phase 2
50
Tianjin
2026-06-23
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
NCT07262164Advanced Malignant Solid Tumor
Shanghai Virogin Biotech Co., Ltd.
Phase 1
30
Hebei
2026-03-18
Recruiting
A Study of MHB009C in Patients With Advanced Solid Tumors
NCT07326488Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Shanghai
2026-03-17
Not yet open
A Study of JSKN027 in Patients With Advanced Solid Tumors
NCT07391644Advanced Malignant Solid Tumor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1
250
Beijing
2026-03-15
Recruiting
A Study of MHB048C in Patients With Advanced Solid Tumors
NCT07192120mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Shanghai
2026-01-16
Recruiting
A Study of MHB042C in Patients With Advanced Solid Tumors
NCT07192107Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Guangzhou
2025-11-27
Recruiting
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
NCT07130383Advanced Breast Cancer, Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 2
210
Shanghai
2025-09-30
Recruiting
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
NCT07126665Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
116
Shanghai
2025-09-18
Not yet open
Phase I/II Study of SCTB39G in Advanced Solid Tumours
NCT07077252Advanced Malignant Solid Tumor
Sinocelltech Ltd.
Phase 1/2
30
Beijing
2025-07-28
Recruiting
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
NCT07050641Advanced Malignant Solid Tumor
Sinocelltech Ltd.
Phase 1/2
110
Beijing
2025-06-23
Recruiting
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
NCT07045454Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1
200
Shanghai
2025-03-31
Recruiting
Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors
NCT06718946Advanced Malignant Solid Tumor
Fudan University
Phase EARLY_PHASE1
38
Shanghai
2024-12-10
Recruiting
A Study of MT027 in Patients with Pleural Malignant Tumors
NCT06726564Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma, Pleural Mesothelioma
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1
18
Beijing
2024-05-15
Recruiting
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
NCT06592417Advanced Malignant Solid Tumor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1
140
Fuzhou, Guangzhou
2024-04-30
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
NCT05477849Advanced Malignant Solid Tumor
Shanghai Virogin Biotech Co., Ltd.
Phase 1
30
Hangzhou
2022-08-23
Active, closed
PRL3-Zumab in Patients With Advanced Solid Tumors
NCT07541001Advanced Malignant Solid Tumor
Intra-IMMUSG Pte Ltd
Phase 2
60
Hangzhou
2021-08-30
Recruiting
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
NCT04165590Advanced Malignant Solid Tumor
CAS Lamvac Biotech Co., Ltd.
Phase 1/2
60
Kunming
2019-10-24
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-malignant-solid-tumor

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies listing the condition Advanced Malignant Solid Tumor.

How many Advanced Malignant Solid Tumor trials are recruiting in China?

14 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Malignant Solid Tumor), 18 studies
PhaseStudiesRecruitingShare
Phase 1/28644.4%
Phase 16533.3%
Phase 23216.7%
Phase EARLY_PHASE1115.6%

Most active sponsors

Lead sponsors with the most studies (Advanced Malignant Solid Tumor)
Lead sponsorStudiesRecruiting
Minghui Pharmaceutical (Hangzhou) Ltd66
Jiangsu Alphamab Biopharmaceuticals Co., Ltd21
Shanghai Virogin Biotech Co., Ltd.22
Sinocelltech Ltd.21
CAS Lamvac Biotech Co., Ltd.11
Fudan University11
Intra-IMMUSG Pte Ltd10
Suzhou Maximum Bio-tech Co., Ltd.11
Tianjin First Central Hospital11
Virogin Biotech Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.